Podcasts
Listen to the latest hemonc news from international experts
The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Post-ASH CLL highlights: BTK inhibitors & degraders, bispecific antibodies, & more!
VJHemOnc recently attended the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, where we gained expert insights into cutting-edge research in hematological malignancies. This podcast series will cover highlights in a variety of disease areas. Today’s episode focuses on chronic lymphocytic leukemia (CLL).
You will hear from experts Jeff Sharman, MD, Willamette Valley Cancer Institute, Eugene, OR, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, and Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia. They discuss key updates on the use of BTK inhibitors in CLL, including the BRUIN CLL-321 (NCT04666038) and AMPLIFY (NCT03836261) trials, as well as the BTK degraders NX-2127 and NX-5948. They then go on to speak about novel approaches being explored, including treatment with the bispecific antibody epcoritamab in the EPCORE-CLL1 (NCT04623541) trial, and the use of sonrotoclax in the BGB-11417-101 (NCT04277637) trial.
Date: 10th January 2025
